Patent Application for Stabilized Galectin-9 Protein Pharmaceutical Formulation
Summary
The USPTO has published a patent application (US20260083671A1) for a stabilized pharmaceutical formulation containing a recombinant stabilized galectin-9 protein. The application details a formulation designed for improved stability through the combination of a buffer and a stabilizer.
What changed
This document is a published patent application from the USPTO detailing a novel pharmaceutical formulation. The application, filed on August 8, 2025, and published as US20260083671A1, describes a stabilized formulation comprising a recombinant stabilized galectin-9 protein, specifically designed for improved stability through the combination of a buffer and a stabilizer.
This publication represents a new intellectual property filing related to drug formulation. While not a regulatory rule, it signals potential future developments in therapeutic products. Companies in the pharmaceutical sector should be aware of this filing as it pertains to potential new drug compositions and may impact their own research and development or patent strategies.
Archived snapshot
Mar 26, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
STABILIZED FORMULATION COMPRISING RECOMBINANT STABILIZED GALECTIN 9 PROTEIN
Application US20260083671A1 Kind: A1 Mar 26, 2026
Inventors
David SONG
Abstract
The present invention relates to a stabilized pharmaceutical formulation comprising a recombinant stabilized galectin-9 protein. More specifically, the invention provides a pharmaceutical formulation with improved stability through the combination of a buffer and a stabilizer.
CPC Classifications
A61K 9/08 A61K 9/19 A61K 38/1732 A61K 47/02 A61K 47/12 A61K 47/183 A61K 47/22 A61K 47/26
Filing Date
2025-08-08
Application No.
19295090
Named provisions
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.